ReviewVascular health and risk management2021
β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?
Review in Vascular health and risk management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 28 citations in OpenAlex.
- Relationships Among Heart Rate Variability, Perceived Social Support, and Hopelessness in Adults With Ischemic Heart Disease.Journal of the American Heart Association · 2024Trial
- Outcome of COVID-19 infection in patients on antihypertensives: A cross-sectional study.World journal of critical care medicine · 2024Article
- Review
- The recent advance and prospect of natural source compounds for the treatment of heart failure.Heliyon · 2024Review
- Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view.Frontiers in pharmacology · 2022Review
- Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register.Frontiers in cardiovascular medicine · 2022Article
- Neuroimmunology of cancer and associated symptomology.Immunology and cell biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.